Description

This market insight provides the list of key marketed products as well key compounds in phase 2 and 3 clinical trials in the global nonmalignant blood disorders market, classified into eight major segments including antianaemics, anticoagulants, antifibrinolytics, fibrinolytics, blood substitutes, plasma expanders, platelet aggregation inhibitors, and other haematologicals. Additionally, an overview of the major on-going phase 3 clinical trials and detailed findings of most promising phase 3 compounds have also been provided.